Evidence map›Paper›PMID 40952453›Full record

ArticleArchives of microbiology2025

Comparative immunogenicity study of two different types of tuberculosis vaccines based on a heterologous boosting strategy.

Xiaochun Wang, Runlin Wang, Jianghong Wang, Zian Zhang, LingYun Kong, Lu Xia, Zhiyang Qi, Haoying Chen

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaochun WangThe First Affiliated Hospital, Anhui University of Science and Technology, Huainan, 232001, China.
Runlin WangDepartment of Pathogen Biology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China.
Jianghong WangDepartment of Pathogen Biology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China. 3376015989@qq.com.
Zian ZhangDepartment of Immunology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China.
LingYun KongDepartment of Pathogen Biology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China.
Lu XiaDepartment of Pathogen Biology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China.
Zhiyang QiDepartment of Pathogen Biology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China.
Haoying ChenDepartment of Pathogen Biology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China.

Funding

Anhui University of Science and Technology Medical Special Cultivation Key Project YZ2023H1B003
6 · The paper itself

Abstract

BCG, one of the oldest vaccines in clinical use, has demonstrated well-documented safety, quality, and efficacy in preventing severe forms of tuberculosis (TB) in neonates. However, its protective efficacy declines significantly in adulthood, failing to prevent pulmonary the TB -a major driver of global TB transmission. To address this limitation, this study systematically evaluated two novel BCG-boosting strategies: a recombinant subunit protein vaccine targeting the Rv2074 antigen and a DNA vaccine encoding the same antigen, both evaluated in murine immunization. Antigen-specific cytokine levels in splenocyte supernatants and serum antibody titers were quantified by ELISA after euthanizing mice at 8 weeks (8w) and 16 weeks (16w) post-immunization. The results indicated that both vaccine types induced robust Th1-type immune responses in mice. Additionally, antigen-specific T cell cytokine secretion was analyzed using flow cytometry combined with intracellular cytokine staining. Experimental data revealed that the BCG + P group exhibited a significant increase in CD4

Indexed as

BCG VaccineImmunization, SecondaryImmunogenicity, VaccineTuberculosisTuberculosis VaccinesAnimalsAntibodies, BacterialAntigens, BacterialCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCytokinesFemaleMiceMice, Inbred BALB CMice, Inbred C57BLMycobacterium tuberculosisAntibodies, BacterialAntigens, BacterialBCG VaccineCytokinesTuberculosis VaccinesVaccines, DNAVaccines, SubunitBCG vaccineDNA vaccineImmunogenicityProtein vaccineTuberculosis

Identifiers

PMID40952453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.